Prevención del ictus en pacientes con fibrilación auricular. Mejorar la protección enla era de la COVID-19

Hindricks, 2021, 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS), Eur HeartJ, 42, 373, 10.1093/eurheartj/ehaa612 Chugh, 2014, Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study, Circulation, 129, 837, 10.1161/CIRCULATIONAHA.113.005119 Krijthe, 2013, Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060, Eur Heart J, 34, 2746, 10.1093/eurheartj/eht280 An, 2019, Causes of death in Japanese patients with atrial fibrillation: the Fushimi Atrial Fibrillation Registry, Eur Heart J Qual Care Clin Outcomes., 5, 3542, 10.1093/ehjqcco/qcy033 Andersson, 2013, All-cause mortality in 272,186 patients hospitalized with incident atrial fibrillation 1995-2008: a Swedish nationwide long-term case-control study, Eur Heart J, 34, 1061, 10.1093/eurheartj/ehs469 Benjamin, 2019, American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee, Heart disease and stroke statistics — 2019 update: a report from the American Heart Association. Circulation, 139, e56 Ceornodolea, 2017, Epidemiology and management of atrial fibrillation and stroke: review of data from four European countries, Stroke Res Treat., 2017, 8593207 Sepehri Shamloo, 2020, Atrial fibrillation and cognitive impairment: new insights and future directions, Heart Lung Circ, 29, 69, 10.1016/j.hlc.2019.05.185 Freeman, 2015, Circ Cardiovasc Qual Outcomes., 8, 393, 10.1161/CIRCOUTCOMES.114.001303 Meyre, 2019, Risk of hospital admissions in patients with atrial fibrillation: a systematic review and meta-analysis, Can J Cardiol, 35, 1332, 10.1016/j.cjca.2019.05.024 Steinberg, 2014, Drivers of hospitalization for patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF), Am Heart J, 167, 735, 10.1016/j.ahj.2014.02.003 Masjuán, 2014, Manejo actual del tratamiento antitrombótico en pacientes con fibrilación auricular no valvular y antecedentes de ictus o ataque isquémico transitorio, Rev Neurol, 59, 25 Wolf, 1991, Probability of stroke: a risk profile from the Framingham Study, Stroke, 22, 312, 10.1161/01.STR.22.3.312 Clua-Espuny, 2012, Estudio Ebrictus. Resultados funcionales, supervivencia y años potenciales de vida perdidos después del primer episodio de ictus, Aten Primaria, 44, 223, 10.1016/j.aprim.2011.04.004 Arauz, 2017, Outcome, Recurrence and Mortality after Non-Valvular Atrial Fibrillation Stroke: Long-Term Follow-Up Study, J Vasc Interv Neurol, 9, 5 Ruddox, 2017, Atrial fibrillation and the risk for myocardial infarction, all-cause mortality and heart failure: A systematic review and meta-analysis, Eur J Prev Cardiol, 24, 1555, 10.1177/2047487317715769 Ugowe, 2019, Atrial fibrillation and mortality risk: seeing the big picture, Eur Heart J Qual Care Clin Outcomes, 5, 6, 10.1093/ehjqcco/qcy050 Barrios, 2014, Uso del tratamiento antitrombótico segun la escala CHA2DS2-VASc en los pacientes con fibrilación auricular en atención primaria, Rev Esp Cardiol, 67, 150, 10.1016/j.recesp.2013.07.010 Hart, 2007, Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation, Ann Intern Med, 146, 857, 10.7326/0003-4819-146-12-200706190-00007 Barrios, 2017, De los ensayos clínicos a la práctica clinica. Evidencias con rivaroxabân en el tratamiento anticoagulante del paciente con fibrilación auricular no valvular, Semergen, 43, 222, 10.1016/j.semerg.2016.01.016 Hylek, 2003, Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation, N Engl J Med, 349, 1019, 10.1056/NEJMoa022913 Cinza-Sanjurjo, 2015, Evaluación del grado de anticoagulación de pacientes con fibrilación auricular en el âmbito de atención primaria de Galicia. Estudio ANFAGAL, Rev Esp Cardiol, 68, 753, 10.1016/j.recesp.2014.04.020 Barrios, 2015, Control de la anticoagulación en pacientes con fibrilación auricular no valvular asistidos en atención primaria en España. Estudio PAULA, Rev Esp Cardiol, 68, 769, 10.1016/j.recesp.2015.04.017 Anguita Sánchez, 2015, Calidad de la anticoagulación con antagonistas de la vitamina K en España: prevalencia de mal control y factores asociados, Rev Esp Cardiol, 68, 761, 10.1016/j.recesp.2014.11.022 Benezet-Mazuecos, 2019, Validación del cuestionario ICUSI: calidad de la anticoagulación en pacientes con fibrilación auricular tratados con antagonistas de la vitamina K, REC CardioClinics, 54, 165, 10.1016/j.rccl.2019.04.004 Contreras Muruaga, 2018, Factores asociados al mal control de la anticoagulación con antivitamina K en pacientes con fibrilación auricular no valvular atendidos en consultas de Medicina Interna y Neurologîa. Estudio ALADIN, Rev Clin Esp, 218, 327, 10.1016/j.rce.2018.04.020 Bertomeu-González, 2015, Quality of anticoagulation with vitamin K antagonists, Clin Cardiol, 38, 357, 10.1002/clc.22397 Roldán Rabadán, 2018, Relation of quality of anticoagulation control with different management systems among patients with atrial fibrillation: Data from FANTASIIA Registry, Eur J Clin Invest, 48, e12910, 10.1111/eci.12910 Morgan, 2009, Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control, Thromb Res, 124, 37, 10.1016/j.thromres.2008.09.016 Bonde, 2018, Outcomes among patients with atrial fibrillation and appropriate anticoagulation control, J Am Coll Cardiol, 72, 1357, 10.1016/j.jacc.2018.06.065 Haas, 2016, Quality of vitamin K antagonist control and 1-year outcomes in patients with atrial fibrillation: a global perspective from the GARFIELD-AF Registry, PLoS One, 11, e0164076, 10.1371/journal.pone.0164076 Rivera-Caravaca, 2018, Reduced time in therapeutic range and higher mortality in atrial fibrillation patients taking acenocoumarol, Clin Ther, 40, 114, 10.1016/j.clinthera.2017.11.014 Barrios, 2013, Rivaroxaban: a once-daily anticoagulant for the prevention of thromboembolic complications, Expert Rev Cardiovasc Ther, 11, 129, 10.1586/erc.12.172 Ruff, 2014, Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a metaanalysis of randomised trials, Lancet, 383, 955, 10.1016/S0140-6736(13)62343-0 Patel, 2011, Rivaroxaban versus warfarin in nonvalvular atrial fibrillation, N Engl J Med, 365, 883, 10.1056/NEJMoa1009638 Granger, 2011, Apixaban versus warfarin in patients with atrial fibrillation, N Engl J Med, 365, 981, 10.1056/NEJMoa1107039 Giugliano, 2013, Edoxaban versus warfarin in patients with atrial fibrillation, N Engl J Med, 369, 2093, 10.1056/NEJMoa1310907 Connolly, 2009, Dabigatran versus warfarin in patients with atrial fibrillation, N Engl J Med, 361, 1139, 10.1056/NEJMoa0905561 Steffel, 2018, The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation, Eur Heart J, 39, 1330, 10.1093/eurheartj/ehy136 January, 2019, Circulation, 140, e125, 10.1161/CIR.0000000000000665 Anguita Sânchez, 2020, Diferencias entre la percepción de los cardiólogos y la realidad sobre la calidad de la anticoagulación con antagonistas de la vitamina K en España, Rev Esp Cardiol, 73, 332, 10.1016/j.recesp.2019.09.018 Escobar, 2016, Therapeutic behavior of primary care physicians in patients with atrial fibrillation taking vitamin K antagonists not adequately controlled, Eur J Intern Med, 30, e17, 10.1016/j.ejim.2016.01.016 Llisterri Caro, 2019, Utilización de los anticoagulantes orales de acción directa en atención Primaria de España. Posicionamiento de SEMERGEN ante la situación actual, Semergen, 45, 413, 10.1016/j.semerg.2019.06.002 Graham, 2015, Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatrán or warfarin for nonvalvular atrial fibrillation, Circulation, 131, 157, 10.1161/CIRCULATIONAHA.114.012061 Coleman, 2016, REal-LIfe evidence of stroke prevention in patients with atrial fibrillation-The RELIEF study, Int J Cardiol, 203, 882, 10.1016/j.ijcard.2015.09.037 Li, 2017, Effectiveness and safety of apixabán versus warfarin in non-valvular atrial fibrillation patients in ‘‘real-world” clinical practice. A propensity-matched analysis of 76,940 patients, Thromb Haemost, 117, 1072, 10.1160/TH17-01-0068 Coleman, 2017, Effectiveness and safety of apixaban, dabigatran, and rivaroxabán versus warfarin in patients with nonvalvular atrial fibrillation and previous stroke or transient ischemic attack, Stroke, 48, 2142, 10.1161/STROKEAHA.117.017474 De Caterina, 2019, Characteristics of patients initiated on edoxabán in Europe: baseline data from edoxabán treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe), BMC Cardiovasc Disord., 19, 165, 10.1186/s12872-019-1144-x Barón-Esquivias, 2020, Use of edoxaban in clinical practice. The ETNA-AF-Europe registry. Comparison with data from Spain, Future Cardiol, 16, 469, 10.2217/fca-2020-0024 Camm, 2016, XANTUS: a real-world, prospective, observational study of patients treated with rivaroxabán for stroke prevention in atrial fibrillation, Eur Heart J, 37, 1145, 10.1093/eurheartj/ehv466 Tamayo, 2015, Characterizing major bleeding in patients with nonvalvular atrial fibrillation: a pharmacovigilance study of 27467 patients taking rivaroxaban, Clin Cardiol, 38, 63, 10.1002/clc.22373 Beyer-Westendorf, 2014, Rates, management, and outcome of rivaroxabán bleeding in daily care: results from the Dresden NOAC registry, Blood, 124, 955, 10.1182/blood-2014-03-563577 Escobar, 2019, Anticoagulantes orales directos frente a antagonistas de la vitamina K en pacientes con fibrilación auricular de la práctica clinica: revision sistemâtica y metanâlisis, Rev Esp Cardiol, 72, 305, 10.1016/j.recesp.2018.02.023 Cerdá, 2019, Facing real-life with direct oral anticoagulants in patients with nonvalvular atrial fibrillation: outcomes from the first observational and prospective study in a Spanish population, J Comp Eff Res, 8, 165, 10.2217/cer-2018-0134 Suárez Fernández, 2018, Seguimiento de las recomendaciones del Informe de Posicionamiento Terapéutico sobre el tratamiento con anticoagulantes orales en pacientes ancianos con fibrilación auricular. Estudio ESPARTA, Med Clin (Bare), 151, 8, 10.1016/j.medcli.2017.07.025 Steinberg, 2018, Frequency and outcomes of reduced dose non-vitamin K antagonist anticoagulants: results from ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II), J Am Heart Assoc, 7, 10.1161/JAHA.117.007633 Camm, 2020, Mortality in patients with atrial fibrillation receiving nonrecommended doses of direct oral anticoagulants, J Am Coll Cardiol, 76, 1425, 10.1016/j.jacc.2020.07.045 Chai-Adisaksopha, 2015, Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials, J Thromb Haemost, 13, 2012, 10.1111/jth.13139 Kupó, 2020, Direct anticoagulants and risk of myocardial infarction, a multiple treatment network meta-analysis, Angiology, 71, 27, 10.1177/0003319719874255 Hohnloser, 2019, Uptake in antithrombotic treatment and its association with stroke incidence in atrial fibrillation: insights from a large German claims database, Clin Res Cardiol, 108, 1042, 10.1007/s00392-019-01437-7 Cowan, 2018, A 10 year study of hospitalized atrial fibrillation-related stroke in England and its association with uptake of oral anticoagulation, Eur Heart J, 39, 2975, 10.1093/eurheartj/ehy411 Forslund, 2018, Improved stroke prevention in atrial fibrillation after the introduction of non-vitamin K antagonist oral anticoagulants, Stroke, 49, 2122, 10.1161/STROKEAHA.118.021990 Maggioni, 2020, Four-year trends in oral anticoagulant use and declining rates of ischemic stroke among 194,030 atrial fibrillation patients drawn from a sample of 12 million people, Am Heart J, 220, 12, 10.1016/j.ahj.2019.10.017 Freixa-Pamias, 2021, Impact of prescription patterns of antithrombotic treatment on atrial fibrillation-related strokes, Curr Med Res Opin, 1, 1 Boriani, 2018, Contemporary stroke prevention strategies in 11 096 European patients with atrial fibrillation: a report from the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) LongTerm General Registry, Europace, 20, 747, 10.1093/europace/eux301 Sociedad Española de Neurologîa. El atlas del ictus. España 2019. Disponible en: https://www.sen.es/images/2020/atlas/Atlas_del_Ictus_de_Espana_version_web. pdf. Consultado 16 Feb 2021. oldán, 2016, En el camino de un mejor uso de los anticoagulantes en la fibrilación auricular no valvular. Propuesta de modificacion del posicionamiento terapéutico UT/V4/23122013, Rev Esp Cardiol, 69, 551, 10.1016/j.recesp.2016.03.004 Escobar Cervantes C, MMartí-Almor J, Pérez Cabeza A, Prades Martí M, Aceituno Mata S. Clinical and economic impact of Direct Oral Anticoagulants increased use in the treatment of nonvalvular atrial fibrillation in Spain based on real-life data. Presentado en International Society for Pharmacoeconomics and Outcomes Research (ISPOR), celebrado en Copenague, del 2 al 6 de Noviembre de 2019. PCV23. Zhou, 2020, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet, 395, 1054, 10.1016/S0140-6736(20)30566-3 Huang, 2020, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, 395, 497, 10.1016/S0140-6736(20)30183-5 Guo, 2020, Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19), JAMA Cardiol, 5, 1, 10.1001/jamacardio.2020.1017 Hendren, 2020, Description and proposed management of the acute COVID-19 cardiovascular syndrome, Circulation, 141, 1903, 10.1161/CIRCULATIONAHA.120.047349 Russo, 2020, Atrial Fibrillation in COVID-19: From epidemiological association to pharmacological implications, J Cardiovasc Pharmacol, 76, 138, 10.1097/FJC.0000000000000854 Rodriguez-Leor, 2020, Impacto de la COVID-19 en el tratamiento del infarto agudo de miocardio con elevacion del segmento ST. La experiencia espanola, Rev Esp Cardiol, 73, 994, 10.1016/j.recesp.2020.07.033 Tejada Meza, 2020, Impact of COVID-19 outbreak on ischemic stroke admissions and in-hospital mortality in North-West Spain, Int J Stroke, 15, 755, 10.1177/1747493020938301 Federación Española de Asociaciones de Anticoagulados (FEASAN). El control del paciente anticoagulado en tiempos de COVID-19 Anâlisis de las medidas adoptadas a nivel estatal y autonomico por las autoridades sanitarias. Disopnible en: https://anticoagulados.info/wp-content/uploads/2020/05/Medidas-Covid_CCAA_vf2.pdf. Consultado 16 Feb 2021.